Business Context and Reporting Period
This Form 8-K Current Report was filed by DarioHealth Corp. on December 19, 2019. The filing discloses the entry into material definitive agreements regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private offering of Series A-3 Preferred Stock.
- Shares Issued: 1,346 shares of Series A-3 Preferred Stock.
- Purchase Price: $1,000 per share.
- Gross Proceeds (Current Offering): $1,346,000.
- Total Aggregate Gross Proceeds: $21.375 million (includes proceeds from Series A, A-1, A-2, A-3, and A-4 offerings closed between December 3 and December 6, 2019).
- Placement Agent Fees: $132,100 cash fee plus $40,380 non-accountable expense allowance.
- Placement Agent Warrants: Warrants to purchase 39,229 shares of Common Stock at an exercise price of $4.98 per share.
Material Changes and Terms
The filing details the terms of the Series A-3 Preferred Stock, which differs from common stock in the following ways:
- Conversion: Convertible at the holder's option into Common Stock at an initial conversion price of $4.98 per share. Automatic conversion occurs upon approval by 50.1% of holders or on the 36-month anniversary of the effective date.
- Dividends: Payable in shares of Common Stock equal to 10% of issuable shares on the 12-month anniversary, 15% on the 24-month anniversary, and 20% on the 36-month anniversary of the effective date.
- Voting Rights: Vote together with Common Stock on an as-converted basis.
- Liquidation Preference: Pari passu with Common Stock and other Series A Preferred Stock classes, subordinate to Senior Securities.
Guidance, Risks, and Contingencies
- Registration Rights: The Company agreed to file a registration statement for the resale of shares issuable upon conversion within 60 days of the final closing.
- Regulatory Status: Securities were issued pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D and are not registered. They may not be resold in the U.S. absent registration or an exemption.
- Disclosure Limitation: The filing explicitly states that representations and warranties in the subscription agreements are not intended for public investors to obtain factual information about the Company's current state of affairs.
Investor Verification Checklist
- Verify the total capital raised ($21.375 million) against the Company's cash position in subsequent 10-K or 10-Q filings.
- Confirm the filing of the registration statement for the resale of converted shares within the 60-day window.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific beneficial ownership limitations on conversion.
- Monitor the dilution impact of the placement agent warrants (39,229 shares) and the dividend accruals on future share counts.